Co-Crystal Polymorphs from a Solvent-Mediated Transformation
Source abstract
Abstract
co-crystals of carbamazepine and isonicotinamide can form through a solvent-mediated transformation process when a dry mixture of the pure crystalline components is suspended in ethanol. First, needle-like crystals (form II) grow while the pure crystalline components dissolve. Eventually plate-like crystals (form I) grow at the expense of the needle-like crystals. Single crystal structure determination showed that form I consists of chains of alternating dimers of carbamazepine and dimers of isonicotinamide. The powder diffraction pattern and the needle-like shape of form II show that it most probably is isostructural to the known 1:1 co-crystal structure of carbamazepine and nicotinamide, consisting of dimers of carbamazepine linked to chains of nicotinamide through hydrogen bonding. In both form I and form II, the pyridine heteronitrogen of isonicotinamide does not participate in hydrogen bonding. Both co-crystal structures have 1:1 stoichiometry, and they are therefore polymorphs. The solvent-mediated transformation showed that form I is the stable form at room temperature. The phase diagram for carbamazepine-isonicotinamide in ethanol shows that an excess of isonicotinamide is optimum to form co-crystals, and that solutions with 1:1 stoichiometry result in carbamazepine crystals or at best mixtures of carbamazepine and co-crystals. Under optimal conditions, determined by the pure component solubilities, the solvent-mediated transformation method is a simple and effective way of searching for co-crystal polymorphs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Analytical Chemistry and Chromatography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Delft University of Technology, Process & Energy Department, Separation Technology, Leeghwaterstraat 44, 2628 CA Delft, The Netherlands, and Avantium Technologies BV, Zekeringstraat 29, 1014 BV Amsterdam, The Netherlands
References (21)
Show source-provided references
1. Vishweshwar P. · J. Pharm. Sci. · 2006 · 95 · 49910.1002/jps.20578 ↗
2. Almarsson, Ö.; Bourghol-Hickey, M.; Peterson, M.; Zaworotko, M. J.; Moulton, B.; Rodriguez-Hornedo, N.PCT Pat. Appns. WO 200407888816, 2004078163, 2004.
3. Trask A. V. · Cryst. Growth Des. · 2005 · 5 · 101310.1021/cg0496540 ↗
4. Childs S. L. · J. Am. Chem. Soc. · 2004 · 126 · 1333510.1021/ja048114o ↗
5. McNamara D. P. · Pharm. Res. · 2006 · 23 · 188810.1007/s11095-006-9032-3 ↗
6. Variankaval N. · Cryst. Growth Des. · 2006 · 6 · 69010.1021/cg050462u ↗
7. Trask A. V. · Mol. Pharmaceutics · 2007 · 4 · 30110.1021/mp070001z ↗
8. Vishwehwar, P.; McMahon, J. A.; Zaworotko, M.J. Crystal Engineering of Pharmaceutical Co-crystals, In Frontiers in Crystal Engineering;Tiekink, E. R. T.; Vittal, J. J., Eds.Wiley:Chichester, 2006; Chapter 2, pp25−4910.1002/0470022612.ch2 ↗
9. Quehenberger H. · Monatsh. Chem. · 1949 · 80 · 59510.1007/BF00898851 ↗
10. Chiarella R. A. · Cryst. Growth Des. · 2007 · 7 · 122310.1021/cg070218y ↗
11. Sreekanth B. R. · Chem. Commun. · 2007 · 237510.1039/b700082k ↗
12. Fleischman S. G. · Cryst. Growth Des. · 2003 · 3 · 90910.1021/cg034035x ↗
13. Seefeldt K. · J. Pharm. Sci. · 2007 · 96 · 114710.1002/jps.20945 ↗
14. Porter W. W. · Cryst. Growth Des. · 2008 · 8 · 1410.1021/cg701022e ↗
15. Aakeröy C. B. · Cryst. Growth Des. · 2003 · 3 · 15910.1021/cg025593z ↗
16. Nehm S. J. · Cryst. Growth Des. · 2006 · 6 · 59210.1021/cg0503346 ↗
17. Seehttp://www.Crystal16.comfor details.
18. Mackay S. · 1999
19. Rodriguez-Hornedo N. · Mol. Pharmaceutics · 2006 · 3 · 36210.1021/mp050099m ↗
20. Shin N. · Chem. Commun. · 2002 · 237210.1039/b207369m ↗
21. Jayansankar A. · Pharm. Res. · 2006 · 23 · 238110.1007/s11095-006-9110-6 ↗